A robustness-based approach to systems-oriented drug design
The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index.
Abstract
Many potential drugs that specifically target a particular protein considered to underlie a given disease have been found to be less effective than hoped, or to cause significant side effects. The intrinsic robustness of living systems against various perturbations is a key factor that prevents such compounds from being successful. By studying complex network systems and reformulating control and communication theories that are well established in engineering, a theoretical foundation for a systems-oriented approach to more effectively control the robustness of living systems, particularly at the cellular level, could be developed. Here, I use examples that are based on existing drugs to illustrate the concept of robustness, and then discuss how a greater consideration of the importance of robustness could influence the design of new drugs that will be intended to control complex systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it is commonly the case in complex biochemical networks that while changes in individual parameters have little effect on the behaviour of biochemical pathways—indeed evolution is thought to have selected for robustness to individual parameter changes”
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The Byzantine generals problem
Lamport, L., Shostak, R., & Pease, M. (1982) · ACM Transactions on Programming Languages and Systems · doi:10.1145/357172.357176 · Cited by 6,023 · cited 1×
“Fail-on failure (also known as Byzantine failure) has been a major problem for communication networks, and is considered to be a crucial problem in complex network systems in genera”
BackgroundDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“A further illustrative case is that of imatinib (Gleevec; Novartis), which is considered as a successful example of a drug that targets the protein product of a disease-causative gen”
BackgroundROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Khan, J., Wei, J. S., Ringnér, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C., et al. (2001) · Nature Medicine · doi:10.1038/89044 · Cited by 2,644
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Kitano, H. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1471 · Cited by 2,278
Self-citationMendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 2,157
El-Ali, J., Sorger, P. K., & Jensen, K. F. (2006) · Nature · doi:10.1038/nature05063 · Cited by 2,102 · cited 1×
“, and microfluidics technologies could provide us with opportunities for high-throughput cell-based screenin”
BackgroundHumanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Lysogenic Conversion by a Filamentous Phage Encoding Cholera Toxin
Waldor, M. K., & Mekalanos, J. J. (1996) · Science · doi:10.1126/science.272.5270.1910 · Cited by 1,879 · cited 1×
“Cholera toxin is encoded in a pathogenicity island (PAI), and is considered to be acquired through horizontal gene transfe”
BackgroundVogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Reverse engineering of biological complexity
Csete, M. E., & Doyle, J. C. (2002) · Science · doi:10.1126/science.1069981 · Cited by 1,215
Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)
Larder, B. A., & Kemp, S. D. (1989) · Science · doi:10.1126/science.2479983 · Cited by 1,163
A comprehensive pathway map of epidermal growth factor receptor signaling
Oda, K., Matsuoka, Y., Funahashi, A., & Kitano, H. (2005) · Molecular Systems Biology · doi:10.1038/msb4100014 · Cited by 1,158
Self-citationFerrell, J. E. (2002) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(02)00314-9 · Cited by 1,131 · cited 1×
“Systems control introduces negative-feedback, positive-feedback, feed-forward regulation and other regulatory loops to maintain the homeostasis of the system, as well as bistable behaviour”
BackgroundUnderstanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism
Nicholson, J. K., & Wilson, I. D. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1157 · Cited by 1,116
Robustness of cellular functions
Stelling, J., Sauer, U., Szallasi, Z., Doyle, F. J., & Doyle, J. (2004) · Cell · doi:10.1016/j.cell.2004.09.008 · Cited by 1,049
BindingDB (2025) · PubMed · doi:10.7270/q2pc374f · Cited by 924
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Metabolite profiling: from diagnostics to systems biology
Fernie, A. R., Trethewey, R. N., Krotzky, A. J., & Willmitzer, L. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1451 · Cited by 844
Targeting the Cell Cycle: A New Approach to Cancer Therapy
Schwartz, G. K., & Shah, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5594 · Cited by 817 · cited 1×
“An experiment using the human colon cancer cell line HCT-116 demonstrated that a sequence of SN-38 (the active metabolite of irinotecan) followed by flavopiridol induced apoptosis at a high rate (about 44%), but a reverse sequence attained only a modest level of apoptosis (about 15%) and SN-38 as a single reagent indu…”
MethodCarlson, J. M., & Doyle, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012582499 · Cited by 814 · cited 1×
“Biological systems have to be robust yet evolvable, which requires trade-offs between robustness, fragility, resource demands and performanc”
BackgroundThe efficiency of multi-target drugs: the network approach might help drug design
CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803 · cited 1×
“Recent studies related to the effects of multiple weak perturbations on biological networks might provide theoretical accounts for the effects of multicomponent drug”
BackgroundMulticomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769
Lévi, F., Zidani, R., & Misset, J.-L. (1997) · The Lancet · doi:10.1016/s0140-6736(97)03358-8 · Cited by 701
Acute leukaemia in bcr/abl transgenic mice
Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P. K., & Groffen, J. (1990) · Nature · doi:10.1038/344251a0 · Cited by 672
Gery, S., Komatsu, N., Baldjyan, L., Yu, A., Koo, D., & Koeffler, H. P. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.038 · Cited by 630 · cited 1×
“, and research into the relationship between circadian rhythms, the cell cycle and tumours is making rapid progres”
BackgroundPotential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy
Larder, B. A., Kemp, S. D., & Harrigan, P. R. (1995) · Science · doi:10.1126/science.7542804 · Cited by 623
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620 · cited 1×
“, and a combination high-throughput screening strategy has been proposed and implemented in stages in the drug discovery pipelin”
BackgroundSystems biology in drug discovery
Butcher, E. C., Berg, E. L., & Kunkel, E. J. (2004) · Nature Biotechnology · doi:10.1038/nbt1017 · Cited by 605 · cited 1×
“Given these limitations, the production of effective combinatorial drugs, drugs with multiple targets and advances in systems biolog”
BackgroundTisdale, M., Kemp, S. D., Parry, N. R., & Larder, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5653 · Cited by 603
Rude Voldborg, B., Damstrup, L., Spang-Thomsen, M., & Skovgaard Poulsen, H. (1997) · Annals of Oncology · doi:10.1023/a:1008209720526 · Cited by 528
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Shah, M. A., & Schwartz, G. K. (2001) · PubMed · Cited by 518
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Kelliher, M. A., McLaughlin, J., Witte, O. N., & Rosenberg, N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6649 · Cited by 514
United States Food and Drug Administration Drug Approval Summary
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., McGuinn, W. D., Morse, D., Abraham, S., Rahman, A., Liang, C., Lostritto, R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0564 · Cited by 503
The “robust yet fragile” nature of the Internet
Doyle, J. C., Alderson, D. L., Li, L., Low, S., Roughan, M., Shalunov, S., Tanaka, R., & Willinger, W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501426102 · Cited by 474
Bow ties, metabolism and disease
Csete, M., & Doyle, J. (2004) · Trends in biotechnology · doi:10.1016/j.tibtech.2004.07.007 · Cited by 468
Kargman, S., Charleson, S., Cartwright, M., Frank, J., Riendeau, D., Mancini, J., Evans, J., & O'Neill, G. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8690211 · Cited by 462
The development of COX2 inhibitors
Flower, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1034 · Cited by 459
Cancer as a robust system: implications for anticancer therapy
Kitano, H. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1300 · Cited by 456 · cited 1×
“From the aspect of robustness trade-offs, diseases can be classified into one or more of the following: a simple disease, with a breach in the robustness that protects the host system from various perturbations; a parasitic disease, in which the mechanisms for robustness are hijacked for the triggering and progression…”
BackgroundSelf-citationEvolution and spread of antibiotic resistance
Normark, B. H., & Normark, S. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01026.x · Cited by 440 · cited 1×
“However, drug-resistant infections involve the emergence of one or more bacteria that acquire drug-resistance, followed by horizontal transfer of genes that are responsible for the drug-resistant phenotyp”
BackgroundMetabolic footprinting and systems biology: the medium is the message
Kell, D. B., Brown, M., Davey, H. M., Dunn, W. B., Spasic, I., & Oliver, S. G. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1177 · Cited by 424
Deregulated expression of the PER1 , PER2 and PER3 genes in breast cancers
Chen, S.-T., Choo, K.-B., Hou, M.-F., Yeh, K.-T., Kuo, S.-J., & Chang, J.-G. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi075 · Cited by 423 · cited 1×
“The observation that circadian rhythms might be deregulated in tumour cells, but not in normal cells, provides one such clue that might enhance the selectivity of therapeutic effect”
BackgroundNeckers, L., & Ivy, S. P. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200311000-00003 · Cited by 400
Small-Molecule Inhibitor of Vibrio cholerae Virulence and Intestinal Colonization
Hung, D. T., Shakhnovich, E. A., Pierson, E., & Mekalanos, J. J. (2005) · Science · doi:10.1126/science.1116739 · Cited by 358 · cited 1×
“cholerae virulence factors, cholera toxin and toxin-coregulated pilus, by inhibiting the transcriptional regulator Tox”
BackgroundThe challenges of modeling mammalian biocomplexity
Nicholson, J. K., Holmes, E., Lindon, J. C., & Wilson, I. D. (2004) · Nature Biotechnology · doi:10.1038/nbt1015 · Cited by 356
A comprehensive map of the toll‐like receptor signaling network
Oda, K., & Kitano, H. (2006) · Molecular Systems Biology · doi:10.1038/msb4100057 · Cited by 352
Self-citationPrinciples of Spread-Spectrum Communication Systems
Torrieri, D. (2022) · Springer eBooks · doi:10.1007/978-3-030-75343-6 · Cited by 350
Drug research: myths, hype and reality
Kubinyi, H. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1156 · Cited by 348
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334 · cited 1×
“However, imatinib efficacy is compromised by the emergence of various mutations of BCR–ABL , as well as drug resistance that is not dependent on BCR–ABL mutation”
BackgroundHighly Optimized Tolerance: Robustness and Design in Complex Systems
Carlson, J. M., & Doyle, J. (2000) · Physical Review Letters · doi:10.1103/physrevlett.84.2529 · Cited by 330 · cited 1×
“Biological systems have to be robust yet evolvable, which requires trade-offs between robustness, fragility, resource demands and performanc”
BackgroundTraditional Chinese medicine an approach to scientific proof and clinical validation
Yuan, R. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00039-5 · Cited by 329
Wang, M., Lamers, R.-J. A. N., Korthout, H. A. A. J., van Nesselrooij, J. H. J., Witkamp, R. F., van der Heijden, R., Voshol, P. J., Havekes, L. M., Verpoorte, R., & van der Greef, J. (2005) · Phytotherapy Research · doi:10.1002/ptr.1624 · Cited by 303 · cited 1×
“Traditional Chinese medicine emphasizes minor interventions over a broad range of factor”
BackgroundBetween genotype and phenotype: protein chaperones and evolvability
Rutherford, S. L. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1041 · Cited by 301 · cited 1×
“A biological example of decoupling is the correction of protein folding by heat-shock proteins (HSP) such as HSP90 (Ref”
BackgroundA prospective epidemiological study
Tod, E. D. M. (1964) · The Lancet · Cited by 278
Can cell systems biology rescue drug discovery?
Butcher, E. C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1754 · Cited by 276
Shimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0933 · Cited by 259
Circadian chronotherapy for human cancers
Lévi, F. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00326-0 · Cited by 258
Circadian-system alterations during cancer processes: A review
Mormont, M. C., & L�vi, F. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970117)70:2<241::aid-ijc16>3.0.co;2-l · Cited by 253
Horrobin, D. F. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1012 · Cited by 248 · cited 1×
“This disappointing outcome highlights the limitations of the single-target–drug paradig”
BackgroundNimmanapalli, R., O’Bryan, E., & Bhalla, K. N. (2001) · PubMed · Cited by 242
The impact of systems approaches on biological problems in drug discovery
Hood, L., & Perlmutter, R. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1004-1215 · Cited by 229 · cited 1×
“Given these limitations, the production of effective combinatorial drugs, drugs with multiple targets and advances in systems biolog”
BackgroundGorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N., & Sawyers, C. L. (2002) · Blood · doi:10.1182/blood-2002-05-1361 · Cited by 227
Rescuing drug discovery: in vivo systems pathology and systems pharmacology
van der Greef, J., & McBurney, R. N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1904 · Cited by 209
Principles of Spread-Spectrum Communication Systems
Torrieri, D. J. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/b99535 · Cited by 208
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
Kakiuchi, S., Daigo, Y., Ishikawa, N., Furukawa, C., Tsunoda, T., Yano, S., Nakagawa, K., Tsuruo, T., Kohno, N., Fukuoka, M., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh331 · Cited by 173
Robustness trade‐offs and host–microbial symbiosis in the immune system
Kitano, H., & Oda, K. (2006) · Molecular Systems Biology · doi:10.1038/msb4100039 · Cited by 161
Self-citationBays, H. E., Dujovne, C. A., McGovern, M. E., White, T. E., Kashyap, M. L., Hutcheson, A. G., & Crouse, J. R. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00007-9 · Cited by 154
Ma, H.-W., Zhao, X.-M., Yuan, Y.-J., & Zeng, A.-P. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth167 · Cited by 152 · cited 1×
“that can be observed in molecular-interaction networks for various functional subsystems, including metabolic network”
BackgroundCancer robustness: Tumour tactics
Kitano, H. (2003) · Nature · doi:10.1038/426125a · Cited by 146 · cited 1×
“From the aspect of robustness trade-offs, diseases can be classified into one or more of the following: a simple disease, with a breach in the robustness that protects the host system from various perturbations; a parasitic disease, in which the mechanisms for robustness are hijacked for the triggering and progression…”
BackgroundSelf-citationTanaka, R. (2005) · Physical Review Letters · doi:10.1103/physrevlett.94.168101 · Cited by 146 · cited 1×
“Recent discoveries related to the scale-richness of molecular interaction networks, as seen in metabolic network”
BackgroundMetabolic Syndrome and Robustness Tradeoffs
Kitano, H., Oda, K., Kimura, T., Matsuoka, Y., Csete, M., Doyle, J., & Muramatsu, M. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s6 · Cited by 146 · cited 1×
“From the aspect of robustness trade-offs, diseases can be classified into one or more of the following: a simple disease, with a breach in the robustness that protects the host system from various perturbations; a parasitic disease, in which the mechanisms for robustness are hijacked for the triggering and progression…”
BackgroundSelf-citationBifurcation Analysis of a Model of Mitotic Control in Frog Eggs
Borisuk, M. T., & Tyson, J. J. (1998) · Journal of Theoretical Biology · doi:10.1006/jtbi.1998.0781 · Cited by 140 · cited 1×
“Such software enables the application of computational models to identify differences in dynamical behaviours between target and off-target cell”
MethodEvett, G. E., Xie, W., Chipman, J. G., Robertson, D. L., & Simmons, D. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1496 · Cited by 133
In Vivo Robustness Analysis of Cell Division Cycle Genes in Saccharomyces cerevisiae
Moriya, H., Shimizu-Yoshida, Y., & Kitano, H. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020111 · Cited by 124 · cited 1×
“Recently, my group has developed a new experimental method called gene tug-of-war (gTOW) to comprehensively and quantitatively measure robustness of cellular functions against quantitative perturbations of gene dosag”
MethodSelf-citationMotwani, M., Jung, C. P., Sirotnak, F. M., She, Y., Shah, M. A., Gönen, M., & Schwartz, G. K. (2001) · PubMed · Cited by 116
Multiple weak hits confuse complex systems: A transcriptional regulatory network as an example
Ágoston, V., Csermely, P., & Pongor, S. (2005) · Physical Review E · doi:10.1103/physreve.71.051909 · Cited by 111 · cited 1×
“Recent studies related to the effects of multiple weak perturbations on biological networks might provide theoretical accounts for the effects of multicomponent drug”
BackgroundMAINTENANCE CHEMOTHERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA: BETTER IN THE EVENING
Rivard, G., Hoyoux, C., Infante‐Rivard, C., & Champagne, J. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91551-x · Cited by 106
A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol
Shah, M. A., Kortmansky, J., Motwani, M., Drobnjak, M., Gonen, M., Yi, S., Weyerbacher, A., Cordon-Cardo, C., Lefkowitz, R., Brenner, B., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2651 · Cited by 101 · cited 1×
“The combination of irinotecan followed by flavopiridol is currently in clinical trial”
BackgroundRobustness of the bistable behavior of a biological signaling feedback loop
Bhalla, U. S., & Iyengar, R. (2001) · Chaos: An Interdisciplinary Journal of Nonlinear Science · doi:10.1063/1.1350440 · Cited by 95 · cited 1×
“Systems control introduces negative-feedback, positive-feedback, feed-forward regulation and other regulatory loops to maintain the homeostasis of the system, as well as bistable behaviour”
BackgroundZarraga, I. G. E., & Schwarz, E. R. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.003 · Cited by 92
Kassouf, W., Dinney, C. P., Brown, G. A., McConkey, D. J., Diehl, J. A., Bar‐Eli, M., & Adam, L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1536 · Cited by 92
Advair: Combination treatment with fluticasone propionate/salmeterol in the treatment of asthma
Nelson, H. S. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.112939 · Cited by 88 · cited 1×
“Multicomponent therapies are increasingly gaining attention, with several marketing successes reported — salmeterol/fluticasone (Advair; GlaxoSmithKline”
BackgroundZipf's Law in Importance of Genes for Cancer Classification Using Microarray Data
Li, W., & Yang, Y. (2002) · Journal of Theoretical Biology · doi:10.1006/jtbi.2002.3145 · Cited by 80 · cited 1×
“, and a theoretical study using microarray data for cancer classification concluded that expression of genes at the middle range of expression levels, rather than top-ranking expression levels, has more importance in improving classification accurac”
BackgroundZsebik, B., Citri, A., Isola, J. J., Yarden, Y., Szöllõsi, J., & Vereb, G. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.11.018 · Cited by 75
Fujie, Y., Yamamoto, H., Ngan, C. Y., Takagi, A., Hayashi, T., Suzuki, R., Ezumi, K., Takemasa, I., Ikeda, M., Sekimoto, M., et al. (2005) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyi130 · Cited by 75 · cited 1×
“For example, in a study using colorectal cancer cell lines (DLD1 and SW480), effects on the order of administration for paclitaxel (Taxol; Bristol–Myers Squibb) and oxaliplatin (Eloxatin, Sanofi–Aventis) have been investigated; a taxol–oxaliplatin sequence had greater growth-inhibitory effects than an oxaliplatin–taxo…”
BackgroundEriguchi, M., Lévi, F., Hisa, T., Yanagië, H., Nonaka, Y., & Takeda, Y. (2003) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2003.08.012 · Cited by 67
New Targeted Approaches in Chronic Myeloid Leukemia
Cortes, J. E., & Kantarjian, H. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.009 · Cited by 49
Gupta, E. K., & Ito, M. K. (2002) · Heart Disease · doi:10.1097/00132580-200203000-00010 · Cited by 46 · cited 1×
“, nicotinic acid/lovastatin (Advicor; Kos Pharmaceuticals”
Nakamura, H., Takamori, S., Fujii, T., Ono, M., Yamana, H., Kuwano, M., & Shirouzu, K. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.12.020 · Cited by 37
Lévi, F. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991773302 · Cited by 29
A Recent Illustration of Some Essentials of Circadian Chronotherapy Study Design
Hrushesky, W. J. M., Wood, P. A., Lévi, F., von Roemeling, R., Bjarnason, G. A., Focan, C., Meier, K., Cornélissen, G., & Franz Halberg, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.042 · Cited by 17
Nelson, H. S. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.114048 · Cited by 5
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
“The relationship between kinetics and systemic responses to perturbations offers an intriguing additional dimension in which network pharmacology strategies can be applied; it also provides a framework for understanding systems response”
BackgroundWang, X., Shen, Y., Wang, S., Li, S., Zhang, W., Liu, X., Lai, L., Pei, J., & Li, H. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx374 · Cited by 1,588
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
“…to the simultaneous action of several drugs, provides new opportunities for the rational development of combination therapies (Smalley et al. 2006; Kitano 2007; Zimmermann et al. 2007; Podolsky and Greene 2011) and exploits the chances for better efficacy, decreased toxicity, and reduced…”
BackgroundMechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
“With such issues in mind, systems-oriented drug design has been increasingly emphasized as a potentially more productive strateg”
BackgroundSynergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
“This requires precise target modulation, which can be thwarted by the compensatory mechanisms available to complex biological system”
Metadata
- Authors
- Kitano, H.
- Affiliations
- Sony Computer Science Laboratories (JP)
- Corresponding author
- Kitano, Hiroaki
- ORCID
- Kitano, Hiroaki
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-02-23
- Volume
- 6
- Issue
- 3
- Pages
- 202-210
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1504533062
- Cited by
- 488
- References
- 105
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 9 · 2023: 6 · 2022: 15 · 2021: 8 · 2020: 18 · 2019: 20 · 2018: 16 · 2017: 25 · 2016: 29 · 2015: 37 · 2014: 30 · 2013: 32 · 2012: 47
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- robustness, biological robustness, complex networks, control theory, communication theory, cellular systems, drug efficacy, adverse drug reactions, systems biology
- MeSH terms
- Animals, Communicable Diseases, Pharmaceutical Preparations, Humans, Models, Theoretical, Neoplasms, Technology, Pharmaceutical, Drug Design, Signal Transduction, Cell Proliferation, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.